These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 15248822

  • 21. Urinary calcium excretion in primary hyperparathyroidism: relationship to 25-hydroxyvitamin d status.
    Bussey AD, Bruder JM.
    Endocr Pract; 2005; 11(1):37-42. PubMed ID: 16033734
    [Abstract] [Full Text] [Related]

  • 22. Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage?
    Carnevale V, Manfredi G, Romagnoli E, De Geronimo S, Paglia F, Pepe J, Scillitani A, D'Erasmo E, Minisola S.
    Clin Endocrinol (Oxf); 2004 Jan; 60(1):81-6. PubMed ID: 14678292
    [Abstract] [Full Text] [Related]

  • 23. [Biological activity of FGF-23 and pathophysiologic role in chronic kidney disease].
    Yamashita T.
    Clin Calcium; 2004 May; 14(5):760-3. PubMed ID: 15577039
    [Abstract] [Full Text] [Related]

  • 24. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism.
    Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y.
    J Am Soc Nephrol; 2007 Oct; 18(10):2683-8. PubMed ID: 17855636
    [Abstract] [Full Text] [Related]

  • 25. Predictors of renal function in primary hyperparathyroidism.
    Walker MD, Nickolas T, Kepley A, Lee JA, Zhang C, McMahon DJ, Silverberg SJ.
    J Clin Endocrinol Metab; 2014 May; 99(5):1885-92. PubMed ID: 24527717
    [Abstract] [Full Text] [Related]

  • 26. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure.
    Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB.
    J Clin Endocrinol Metab; 1988 Nov; 67(5):876-81. PubMed ID: 3182962
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure.
    Kates DM, Sherrard DJ, Andress DL.
    Am J Kidney Dis; 1997 Dec; 30(6):809-13. PubMed ID: 9398125
    [Abstract] [Full Text] [Related]

  • 32. Lower total 25-hydroxyvitamin D but no difference in calculated or measured free 25-hydroxyvitamin D serum levels in patients with primary hyperparathyroidism.
    Meng L, Su C, Shapses SA, Al-Dayyeni A, He Y, Wang X.
    J Steroid Biochem Mol Biol; 2020 May; 199():105616. PubMed ID: 32027935
    [Abstract] [Full Text] [Related]

  • 33. Reelevation of parathyroid hormone level after parathyroidectomy in patients with primary hyperparathyroidism: importance of decreased renal parathyroid hormone sensitivity.
    Yamashita H, Noguchi S, Moriyama T, Takamatsu Y, Sadanaga K, Uchino S, Watanabe S, Ogawa T.
    Surgery; 2005 Apr; 137(4):419-25. PubMed ID: 15800489
    [Abstract] [Full Text] [Related]

  • 34. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.
    Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M.
    Kidney Int; 2005 Mar; 67(3):1171-8. PubMed ID: 15698459
    [Abstract] [Full Text] [Related]

  • 35. Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism.
    Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Rejnmark L, Brixen K, Mosekilde L.
    Eur J Endocrinol; 2008 Dec; 159(6):719-27. PubMed ID: 18787045
    [Abstract] [Full Text] [Related]

  • 36. Ultraviolet B activated 1,25(OH)(2)D affects the level of fibroblast growth factor-23 in human.
    Lee JH, Kim KM, Shin DY, Choi HS, Kim DY, Park YK, Lim SK, Rhee Y.
    Endocr J; 2013 Dec; 60(1):81-6. PubMed ID: 22986488
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?
    Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SM, Jüppner H, Wolf M.
    Kidney Int; 2006 Oct; 70(8):1486-94. PubMed ID: 16941023
    [Abstract] [Full Text] [Related]

  • 39. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial.
    Rolighed L, Rejnmark L, Sikjaer T, Heickendorff L, Vestergaard P, Mosekilde L, Christiansen P.
    J Clin Endocrinol Metab; 2014 Mar; 99(3):1072-80. PubMed ID: 24423366
    [Abstract] [Full Text] [Related]

  • 40. Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature.
    Shah VN, Shah CS, Bhadada SK, Rao DS.
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):797-803. PubMed ID: 24382124
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.